Эзомепразол

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Эзомепразол

What is Esomeprazole?

Esomeprazole is the International Nonproprietary Name (INN) for an active pharmaceutical ingredient belonging to the Proton Pump Inhibitor (PPI) class of medications. This drug works by significantly and selectively reducing the amount of acid produced in the stomach. Chemically, it is known as the S-isomer of omeprazole, a specific distinction noted for contributing to its consistent effect and high effectiveness in acid suppression.


Key Recognition and Uses

Esomeprazole's role in managing acid-related conditions is clinically recognized by major health agencies worldwide. The medication is utilized for conditions resulting from excessive stomach acid exposure. A typical scenario for its use includes the short-term treatment of frequent and persistent symptoms associated with Gastroesophageal Reflux Disease (GERD), such as heartburn and acid regurgitation.


Formulations and Differentiation

While available in both prescription and over-the-counter (OTC) strengths, esomeprazole is commonly known by its original brand name, Nexium. To protect the active ingredient from being degraded by the acidic environment of the stomach, the medication is typically formulated as a delayed-release capsule or tablet. This often utilizes a specialized technology called the Multiple-Unit Pellet System (MUPS) which ensures the drug passes intact into the small intestine for absorption. For specific prescription uses, esomeprazole is also utilized as part of combination regimens to eradicate the Helicobacter pylori bacterium, a common cause of peptic ulcers.

Advertisements

What side effects are possible with Эзомепразол?

Possible Side Effects and Safety Information

The information in this section outlines the adverse effects and safety characteristics of Esomeprazole as officially documented by government regulatory agencies (such as the FDA and EMA). It is based strictly on label information.


Documented Adverse Reactions and Frequency

Adverse reactions are classified by frequency, with common effects primarily involving the gastrointestinal and nervous systems:

  • Common ( ge 1/100 ): Headache, abdominal pain, diarrhea, constipation, flatulence, nausea, and vomiting.
  • Uncommon ( ge 1/1,000 ): Dizziness, insomnia, rash, itching, and increased liver enzymes.
  • Rare ( ge 1/10,000 ): Hypersensitivity reactions (including angioedema), low sodium (Hyponatraemia), and blurred vision. Effects on the blood and lymphatic system, such as Leukopenia and Thrombocytopenia, are also documented.
  • Very Rare ( < 1/10,000 ): Severe conditions including Agranulocytosis, Hepatic failure, and severe skin reactions like Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Serious Safety Considerations

Regulatory labeling specifies several serious safety concerns that may occur, though often rarely:

Safety Consideration Context in Regulatory Labeling
Acute Interstitial Nephritis (AIN) Reported as a serious adverse reaction that may occur at any time during therapy.
Fracture Risk Associated with long-term use (one year or longer) and high doses, particularly in older adults.
Hypomagnesaemia Low magnesium levels reported with use for at least three months, with most cases occurring after a year of therapy.
Drug Interactions Potential for reduced antiplatelet activity when co-administered with Clopidogrel, which is a safety constraint.
C. difficile Risk Therapy may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD).
Advertisements

Overdose and Emergency Response

The regulatory overdose profile for Esomeprazole is defined by the limited clinical experience and the reliance on general supportive measures for management.

The official regulatory documentation reports very limited experience with deliberate overdose. Manifestations observed following high-dose oral exposure (e.g., 280 mg) are described as transient in nature and were limited to gastrointestinal symptoms and general weakness. Regulatory information documents that high single doses (80 mg oral) and high intravenous doses (308 mg over 24 hours) were clinically uneventful. No severe or life-threatening outcomes are explicitly documented as direct results of acute overdose in the official labels.

Any suspected overdose requires immediate medical attention. The treatment strategy mandated by regulatory authorities is entirely symptomatic and relies exclusively on general supportive measures being utilized. Official prescribing information confirms that no specific antidote is known for Esomeprazole. Additionally, the substance is not readily dialyzable due to its extensive plasma protein binding. Consequently, regulators state that specific recommendations for treatment beyond supportive care cannot be given. No population-specific acute overdose considerations are detailed in the official regulatory documents.

Advertisements

Therapeutic Uses of Эзомепразол

Main Uses and Therapeutic Benefits

Ezomeprazole is a proton pump inhibitor (PPI) designed to reduce the production of stomach acid. By inhibiting the enzyme system known as the "acid pump" within the gastric parietal cells, it lowers the overall acidity of the digestive environment. This mechanism is utilized to treat various conditions where a reduction in gastric acid is necessary for symptom relief or tissue healing.

Gastroesophageal Reflux Disease (GERD)

The primary application of ezomeprazole is the management of gastroesophageal reflux disease. This condition occurs when stomach acid flows back into the esophagus, causing irritation and discomfort.

  • Erosive Esophagitis: Ezomeprazole is used to heal the inflammation and small ulcers (erosions) in the lining of the esophagus caused by chronic acid exposure.
  • Maintenance of Healing: After the initial recovery of the esophageal lining, low-dose treatment helps prevent the recurrence of erosions.
  • Symptomatic GERD: It is also used to address frequent heartburn and acid regurgitation in patients who do not have visible damage to the esophagus.

Gastric and Duodenal Ulcers

Ezomeprazole plays a significant role in the treatment and prevention of peptic ulcer disease. By maintaining a higher pH level in the stomach, it creates an environment conducive to the natural healing of the mucosal lining.

  • NSAID-Associated Ulcers: For individuals requiring long-term treatment with non-steroidal anti-inflammatory drugs (NSAIDs), ezomeprazole is used to heal existing gastric ulcers and reduce the risk of developing new ones.
  • H. pylori Eradication: In combination with specific antibacterial regimens, ezomeprazole is used to treat duodenal ulcers associated with Helicobacter pylori infection. Reducing acid levels increases the effectiveness of the antibiotics used to eliminate the bacteria.

Hypersecretory Conditions

In rare clinical cases where the stomach produces excessive amounts of acid, such as Zollinger-Ellison syndrome, ezomeprazole is used to manage and maintain acid secretion at safe levels. This long-term management helps prevent the severe complications typically associated with these pathological hypersecretory states.

Therapeutic Benefits

The primary benefit of ezomeprazole is its ability to provide prolonged acid suppression. Unlike antacids, which neutralize existing acid, ezomeprazole prevents acid production at the source. This leads to sustained symptom relief, improved quality of life for those with chronic acid-related disorders, and the prevention of long-term complications such as esophageal strictures or Barrett’s esophagus.

Advertisements

Eligibility and Restrictions for Use

Esomeprazole (or its salts, such as esomeprazole magnesium or sodium) is intended for use in adults and pediatric patients. Eligibility is defined by formal contraindications and restrictions based on regulatory documents.

Contraindicated Populations

  • Patients with a documented hypersensitivity (allergy) to esomeprazole, any substituted benzimidazoles (e.g., omeprazole), or any components of the drug's formulation.
  • Patients receiving the antiretroviral drugs nelfinavir or rilpivirine concurrently.

Age-Related Eligibility

  • Pediatric Use: Use is established for certain conditions in pediatric patients as young as one month of age (e.g., erosive esophagitis). For symptomatic GERD, use is established starting at one year of age. Use in infants less than one month is not established.

Special Population Restrictions

  • Severe Hepatic Impairment (Child-Pugh Class C): Use is restricted; the recommended maximum daily dose must be reduced to 20 mg.
  • Severe Renal Impairment: Use is generally recommended with caution or is not recommended due to limited clinical experience in this population (varies by formulation).
  • Pregnancy and Lactation: Use during pregnancy or while breastfeeding requires a clinical assessment of risk versus benefit, with some documents advising caution or considering discontinuation during nursing.
Advertisements

What should I know about interactions with other medicines?

Esomeprazole's official interaction profile is defined by its two primary effects on co-administered medicinal products: altering gastric pH and inhibiting the CYP2C19 metabolic enzyme.

The resulting change in gastric pH means medicines dependent on stomach acid for absorption, such as Ketoconazole and Erlotinib, may experience decreased systemic exposure. Conversely, the exposure of medicines like Digoxin can be officially increased. The CYP2C19 inhibition pathway may lead to increased plasma concentrations of medicines metabolized primarily by this enzyme.

Certain combinations are subject to mandatory regulatory constraints. Concomitant use with Nelfinavir and Rilpivirine is formally contraindicated due to significant reduction in the antiretrovirals' plasma levels. Co-administration with the antiplatelet agent Clopidogrel is officially advised to be avoided because it reduces the concentration of the active metabolite. For high-dose Methotrexate and Tacrolimus, exposure may be significantly increased, and temporary discontinuation of esomeprazole is noted in regulatory text. When co-administering with Warfarin, mandatory monitoring of the International Normalized Ratio (INR) is required. Furthermore, when co-administering with certain antiretrovirals like Atazanavir, specific time separation (e.g., several hours) is noted in regulatory text to mitigate reduced exposure. The herbal product St. John’s Wort should be avoided as it can reduce esomeprazole exposure.

Advertisements

Mechanism of Action

Irreversible Covalent Inhibition

Esomeprazole functions as a pro-drug that is activated by the acidic environment within the parietal cells of the stomach. Once activated, it targets the H^+/K^+-ATPase (Proton Pump), forming a permanent, covalent bond with specific enzyme sites. This irreversible interaction physically locks the pump in an inactive state, inhibiting the function of the final common pathway of gastric acid production.


Sustained Reduction in Gastric Acidity

By blocking the Proton Pump, the drug ceases the transfer of hydrogen ions ( H^+) into the stomach lumen, regardless of the stimuli (like hormones or nerve signals). This cessation of the terminal step of secretion leads to the core physiological consequence: a significant and sustained elevation of the intragastric pH (decreased acidity). The duration of this effect is dictated by the rate at which the stomach cells synthesize new H^+/ K^+-ATPase enzymes to replace those that have been irreversibly inhibited.

Advertisements

Dosage and Administration Information

How to Use Esomeprazole

Esomeprazole is used according to specific administration patterns. The primary route is Oral, while the Intravenous (IV) route is reserved for short-term use when oral intake is not possible, or in specific acute care settings.


Administration Protocol

Usage Aspect Guideline Contextual Principle
Timing Take the oral dose at least one hour before meals. This maximizes absorption and ensures the medicine's integrity.
Oral Handling Delayed-release forms must be swallowed whole; they should not be chewed or crushed. The specialized coating must remain intact to prevent degradation by stomach acid.
Dosing Frequency Typically Once Daily (e.g., 20 mg or 40 mg), but may be Twice Daily for high-dose regimens. Most conditions require daily dosing; high-secretory disorders or combination therapies require divided doses.
Course Duration Short-term use ranges from 4 to 8 weeks for healing; maintenance use may extend up to 6 months. The total duration is specified for each approved condition.

Special Procedural Requirements

The standard dosing regimen requires adjustment for certain populations; for patients with severe hepatic impairment, the maximum daily oral dose is limited to 20 mg. Intravenous administration, which may include an 80 mg loading dose followed by continuous infusion, is restricted to a maximum of 10 days, after which a transition to oral therapy is mandated.

If an oral dose is missed, the advice is to take it as soon as possible, but if it is nearly time for the next scheduled dose, the missed dose should be skipped to prevent taking two doses simultaneously.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Evidence on Pharmacological Action

Preclinical research has investigated potential pharmacological actions, noting that the compound belongs to the class of proton pump inhibitors (PPIs). Initial laboratory studies explored potential areas of effect related to gastric acid secretion.


Efficacy in Adult Population

The clinical development program for esomeprazole included multiple Phase 3 Randomized Controlled Trials (RCTs) investigating its use in adults for conditions such as erosive esophagitis and gastroesophageal reflux disease (GERD).

Primary Efficacy Findings

RCTs have demonstrated a statistically significant difference compared to placebo in reducing the duration and severity of acid exposure, which is a key measure in managing reflux-related conditions.

  • Studies were designed to assess whether treatment led to a reduction in symptom severity and rates of esophageal healing over the study period.
  • Research has also explored the time required to achieve symptomatic relief after treatment initiation.

Long-term Data

Open-label extension studies have followed patients for extended periods, evaluating the maintenance of effects and the safety profile in a non-controlled setting beyond the initial treatment phase.


Safety and Tolerability

Research has documented specific events across the clinical trial program. The safety profile has been a subject of ongoing investigation in post-marketing surveillance.

Special Populations

Research has evaluated the safety profile when studied in certain adolescent populations (age 12–17). The profile was generally observed to be consistent with the adult population.

Potential Interactions

Research has examined potential interactions with commonly co-administered medications, including, but not limited to, specific antiplatelet agents and antifungals. Always consult a healthcare professional regarding drug interactions.


Comparison to Other Treatments

Head-to-head trials have compared esomeprazole with other proton pump inhibitors, primarily assessing differences in symptom control, tolerability, and rates of side effects.

Key Studies & References

  1. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Эзомепразол (FAQ)


Q: Does esomeprazole cause a loss of appetite?

Official product information, based on clinical trials, indicates that a decrease in appetite has been reported as a common side effect of esomeprazole. This is considered an adverse reaction that is documented in the official labeling.


Q: Can esomeprazole be used for gastroprotection with aspirin?

Yes, one of the official approved indications for esomeprazole is for the risk reduction of stomach ulcers associated with the use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which includes drugs like aspirin. This indication is typically noted for adults who are considered at higher risk, such as those over 60 years of age or with a documented history of ulcers, and who require continuous NSAID therapy.


Q: Can esomeprazole cause tolerance (meaning it stops working after long-term use)?

Regulatory documents do not indicate that esomeprazole is known to stop working due to developing drug tolerance. However, official information emphasizes that patients who use the medicine long-term are typically monitored by a healthcare professional for potential chronic safety concerns.


Q: Is a generic version of esomeprazole available for OTC use?

Yes, the active ingredient, esomeprazole, is available in generic formulations, specifically for over-the-counter (OTC) use. These OTC versions are typically sold under their chemical name (esomeprazole magnesium) for the treatment of frequent heartburn.


Q: Do I need to space out when I take my thyroid medication (levothyroxine) and esomeprazole?

The official interaction profile states that co-administration with medicines whose absorption is affected by changes in stomach acidity, such as certain thyroid medications, requires clinical monitoring. The official interaction information notes that monitoring is necessary to help ensure proper systemic exposure of the thyroid medication.


Q: Are there any mood or anxiety side effects listed on the drug label?

Official product documents classify insomnia (difficulty sleeping) as an uncommon psychiatric disorder associated with the medicine. Furthermore, regulatory labeling notes that feelings such as anxiety or light-headedness, particularly when occurring alongside chest pain, are serious symptoms noted in regulatory labeling.


Q: What should I do if I think I'm allergic to esomeprazole?

The official product information states that hypersensitivity (an allergic reaction) to esomeprazole or similar drugs is a formal contraindication for its use. The official adverse reaction reports note that rare but serious hypersensitivity reactions, such as anaphylactic shock or swelling (angioedema), have occurred.


Q: Does esomeprazole contain lactose, and is that an issue for lactose intolerance?

Regulatory documentation specifies that some formulations of esomeprazole, such as certain gastro-resistant tablets, include lactose monohydrate as an inactive ingredient (excipient). This information is relevant to patients with lactose intolerance, who may wish to review the inactive ingredients for their specific product formulation.


Q: Can children 2 years old use esomeprazole?

Official regulatory indications for esomeprazole cover its use in pediatric patients as young as one year of age for certain approved conditions. The drug label contains specific information regarding its use and appropriate administration in children within the 1-year to 11-year age range.


Q: Can I stop taking esomeprazole suddenly, or will I have withdrawal symptoms?

Abruptly discontinuing esomeprazole may lead to a temporary increase in stomach acid production, which is a known physiological effect and can cause symptoms to return. Regulatory documents suggest that a gradual reduction in the dose may be a consideration.

Advertisements

How should Эзомепразол be stored and disposed of?

How to Store and Dispose of Esomeprazole

Official regulatory documents define strict conditions for the storage and disposal of Esomeprazole to ensure product quality and safety.


Storage Requirements

Esomeprazole must be stored at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F). The medication must be kept in the original container and protected from moisture and light. It is essential to keep the container tightly closed and store the medicine out of the sight and reach of children.


Handling and Disposal

If the capsule contents are mixed with food or liquid for administration, the mixture must be used immediately and any remainder discarded. Unused or expired Esomeprazole must be disposed of according to local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Эзомепразол found in:

A-Z Index: